Pengguguran perubatan

Mifepriston/misoprostol
Kombinasi
Mifepriston	Modulator reseptor progesteron
Misoprostol	Prostaglandin
Data klinikal
Nama dagang	Mifegymiso, Medabon Combipack
Kod ATC	G03XB51 (WHO) ;
Status perundangan
Status perundangan	KA: Rx sahaja ; UK: POM (Preskripsi sahaja) ; EU: Rx sahaja ;

Pengguguran perubatan
Latar belakang
Jenis pengguguran	Perubatan
Penggunaan pertama	Amerika Syarikat 1979 (karboprost),; Jerman Selatan 1981 (sulprostone),; Jepun 1984 (gemeprost),; Perancis 1988 (mifepristone),; Amerika Syarikat 1988 (misoprostol)
Tempoh kehamilan	3–24+ minggu
Penggunaan
	Pengguguran perubatan sebagai peratusan dari semua pengguguran
Perancis	64% (2016)
Sweden	92% (2016)
UK: Eng. & Wales	62% (2016)
UK: Scotland	83% (2016)
Amerika Syarikat	39% (2017)
	Infobox references

Pengguguran perubatan, berlaku apabila ubat-ubatan yang ditetapkan secara perubatan ( ubat ) digunakan untuk menyebabkan pengguguran. Rejimen khas terdiri daripada gabungan ubat-ubatan, dengan mifepriston diikuti dengan misoprostol sebagai rejimen abortifasien paling biasa.^[4] Mifepriston diikuti dengan misoprostol untuk pengguguran dianggap selamat dan berkesan sepanjang usia kehamilan.^[5] Apabila mifepristone tidak tersedia, misoprostol sahaja boleh digunakan. Selain mifepriston/misoprostol, ubat lain boleh digunakan bergantung pada ketersediaan dan pertimbangan khusus pesakit.

Prosedur perubatan untuk mendorong pengguguran secara fizikal yang tidak menggunakan ubat secara amnya disebut sebagai pengguguran pembedahan.

Rujukan

^ "Mifegymiso Product Monograph" (PDF). Health Canada.
^ "Medabon - Combipack of Mifepristone 200 mg tablet and Misoprostol 4 x 0.2 mg vaginal tablets - Summary of Product Characteristics (SmPC)". (emc). 3 February 2020. Dicapai pada 19 January 2021.
^ https://www.ema.europa.eu/documents/psusa/mifepristone/misoprostol-list-nationally-authorised-medicinal-products-psusa/00010378/202005_en.pdf
^ Medical management of abortion. World Health Organization. Geneva, Switzerland. January 30, 2019. m/s. 24. ISBN 978-9241550406. OCLC 1084549520.CS1 maint: others (link)
^ Safe abortion: technical and policy guidance for health systems-2nd ed. Italy: WHO. 2012. m/s. 42. ISBN 9789241548434.

Pautan luar

WHO Scientific Group on Medical Methods for Termination of Pregnancy (December 1997). Medical methods for termination of pregnancy. Technical Report Series, No. 871. Geneva: World Health Organization. ISBN 978-92-4-120871-0. WARNING: LINK GIVES ONLY THE FIRST PAGE OF THE REPORT; THE REST IS LISTED AS "OUT OF PRINT"
Royal College of Obstetricians and Gynaecologists (November 23, 2011). The care of women requesting induced abortion. Evidence-based clinical guideline number 7 (PDF) (ed. 3rd rev.). London: RCOG Press. Diarkibkan daripada yang asal (PDF) pada May 29, 2012.
ICMA (2013). "ICMA Information Package on Medical Abortion". Chișinău, Moldova: International Consortium for Medical Abortion (ICMA).
The official protocol of the clinical trial of the "reversal" regimen is here: Ujian klinikal bernombor NCT03774745 bagi "Blocking Mifepristone Action With Progesterone" di ClinicalTrials.gov

[1] "Mifegymiso Product Monograph" (PDF). Health Canada.

[2] "Medabon - Combipack of Mifepristone 200 mg tablet and Misoprostol 4 x 0.2 mg vaginal tablets - Summary of Product Characteristics (SmPC)". (emc). 3 February 2020. Dicapai pada 19 January 2021.

[3] ttps://www.ema.europa.eu/documents/psusa/mifepristone/misoprostol-list-nationally-authorised-medicinal-products-psusa/00010378/202005_en.pdf

[4] Medical management of abortion. World Health Organization. Geneva, Switzerland. January 30, 2019. m/s. 24. ISBN 978-9241550406. OCLC 1084549520.CS1 maint: others (link)

[5] Safe abortion: technical and policy guidance for health systems-2nd ed. Italy: WHO. 2012. m/s. 42. ISBN 9789241548434.

[1]

[2]

[3]

[4]

[5]